Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma

INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify thresholds correlating to outcomes. METHODS: Retr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Surg Oncol
Hlavní autoři: Al Abbas, Amr I., Zenati, Mazen, Reiser, Caroline J., Hamad, Ahmad, Jung, Jae Pil, Zureikat, Amer H., Zeh, Herbert J., Hogg, Melissa E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7996002/
https://ncbi.nlm.nih.gov/pubmed/31898105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08156-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky